While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Kymera Therapeutics, Inc. (KYMR) shares ended the last trading session 23.4% higher at $39.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.7% loss over the past four weeks. ...